Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Advancing Transcatheter Mitral Valve Repair

Project description

Innovative heart valve replacement

Millions worldwide suffer from mitral valve regurgitation, where blood leaks back into the heart's left atrium. Untreated, this valve dysfunction leads to heart failure and death. Due to the invasiveness of current therapies, fewer than 5 % of seriously ill patients receive treatment, underscoring the need for improved therapeutic strategies. Funded by the European Innovation Council, the Angelvalve Project AVVie has developed the Mitral Butterfly (MB) system, an innovative solution designed to restore proper valve function. The flexible hemi-valve MB, as a minimally invasive procedure, can be delivered through a catheter. A unique passive stabilisation concept without active trauma to the myocardium prevents the MB stent from migrating. Enhanced material memory allows the MB to self-expand upon release, requiring minimal manipulation during placement.

Objective

The Mitral butterfly implant is a posterior leaflet augmentation device which functions to prevent excessive posterior leaflet motion. The implant comprises a)a Nitinol frame designed to sit comfortably within the anatomy of the heart and to provide the overall structure of the implant,b)an artificial leaflet, in the form of a flexible mesh which serves to restrict the prolapsing leaflet and provide a surface for adequate coaptation, and c)a method of anchoring. The implant can be folded into a catheter to facilitate delivery and be deployed in the target region with minimal actuation. The shape memory capabilities of nitinol allow the implant to self-expand when released, and the design of the frame ensures the correct orientation within the valve, consequently, the procedure involves minimal actuated steps with the main mechanical complexity arising from the anchorage. The anchorage itself is achieved with a secondary self-expanding nitinol mechanism.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2022-ACCELERATOR-01

See all projects funded under this call

Coordinator

AVVIE GMBH
Net EU contribution
€ 2 499 999,00
Address
LAZARETTGASSE 12
1090 Wien
Austria
SME
Yes
Region
Ostösterreich Wien Wien
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 8 748 750,00